Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Exclusion Criteria

• •Significant renal impairment (creatinine ≥1.4 mg\\dL females or ≥1.5 mg\\dL males)
• •Planned coronary intervention or planed surgical intervention (PCI or CABG)
• •Planned surgical intervention
• •Recent (\<30 day) acute coronary syndrome (ACS)
• •Hypersensitivity to either of the study drug components
• •History of lactic acidosis
• •Type I diabetes
• •Current Hb A1c \>9%
• •Current Insulin treatment
• •Active treatment with GLP-1 or DPP4i medication
• •Hepatic impairment or ALT\\AST elevations beyond X2 upper normal limit or known hepatic failure
• •Inability to comply with study protocol
• •Active malignancy other than basal cell carcinoma (BCC)
• •Clinically advanced congestive heart failure - NYHA III-IV
• •Severe left ventricular dysfunction (LVEF\<30%) with NYHA II or any NYHA class with documented recent heart failure decompensation (\<3 months)
• •Severe stable cardiac angina CCS III - IV or Unstable angina
• •Chronic inflammation (i.e. IBD, Lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection)
• •Pregnancy, lactation or child-bearing potential